Compare IMPP & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMPP | CABA |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | Greece | United States |
| Employees | 49 | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.6M | 319.6M |
| IPO Year | N/A | 2019 |
| Metric | IMPP | CABA |
|---|---|---|
| Price | $5.03 | $3.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 540.2K | ★ 4.4M |
| Earning Date | 05-22-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.79 | N/A |
| Revenue Next Year | $6.97 | N/A |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.53 | $1.26 |
| 52 Week High | $6.57 | $4.23 |
| Indicator | IMPP | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 51.65 |
| Support Level | $4.04 | $2.17 |
| Resistance Level | $5.26 | $3.54 |
| Average True Range (ATR) | 0.22 | 0.34 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 62.94 | 41.85 |
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.